Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Arcturus Therapeutics Holdings Inc (ARCT) USD0.001

Sell:$10.82 Buy:$10.90 Change: $0.37 (3.52%)
Market closed |  Prices as at close on 10 December 2019 | Switch to live prices |
Change: $0.37 (3.52%)
Market closed |  Prices as at close on 10 December 2019 | Switch to live prices |
Change: $0.37 (3.52%)
Market closed |  Prices as at close on 10 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Arcturus Therapeutics Ltd. is a ribonucleic acid (RNA) medicines company. The Company owns Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR) lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers. The Company’s diverse pipeline of RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis and vaccines. The Company’s versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA and gene editing therapeutics. The Company's UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes.

Contact details

10628 Science Center Dr Ste 200
United States
+1 (858) 9002660

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$150.17 million
Shares in issue:
10.72 million
United States
US dollar

Key personnel

  • Peter Farrell
    Chairman of the Board
  • Joseph Payne
    President, Chief Executive Officer, Director
  • Andrew Sassine
    Chief Financial Officer
  • Padmanabh Chivukula
    Chief Operating Officer, Chief Scientific Officer
  • Kevin Skol
    Senior Vice President - Business Development & Alliance Management
  • K. Kummerfeld
    Vice President - Finance, Corporate Controller
  • Suezanne Parker
    Vice President - Translational Biology

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.